News Sentiment

CBIO sentiment intelligence

Crescent Biopharma, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 14.75 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

87/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-14.9% over one week, -16.6% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 87/100 classification
One-week reaction -14.9% Price reacting lower
Trend fit Trend active -16.6% over four weeks
Fair value 1.6% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 40
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
GlobeNewswire 7
Market source 6
TradingView 6
Quartr 3
Moomoo 3
Quiver Quantitative 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 43
Earnings 12
Deals and strategy 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Stock Titan Direct company coverage

Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal

Fairmount Funds Management LLC and its affiliates, including Fairmount Healthcare Fund II L.P., now beneficially own 16.50% of Crescent Biopharma (CBIO), totaling 6,593,385 Ordinary Shares as of July 16, 2026. This increased stake follows the purchase of 853,450 Ordinary Shares a

Tone
Positive 65/100
Event
Deals and strategy
Published
21 Jul 2026 07:41
Source
Stock Titan
Bitget Direct company coverage

Fairmount Healthcare Fund II LP acquires 853,450 Crescent Biopharma shares for $12.38 million

Fairmount Healthcare Fund II LP has acquired 853,450 ordinary shares of Crescent Biopharma at $14.5 each, increasing its total stake to 3,601,316 shares. Additionally, the fund purchased 525,897 pre-funded warrants at the same price, bringing its warrant position to 2,294,037. To

Tone
Positive 71/100
Event
Deals and strategy
Published
21 Jul 2026 02:09
Source
Bitget
Stock Titan Direct company coverage

Insider fund at Crescent Biopharma (NASDAQ: CBIO) buys 1.38M shares, warrants

Fairmount Healthcare Fund II L.P., an entity linked to Crescent Biopharma (NASDAQ: CBIO), recently acquired 853,450 ordinary shares and 525,897 pre-funded warrants, totaling 1.38 million share equivalents. These transactions, executed on July 16, 2026, increased Fairmount's indir

Tone
Positive 82/100
Event
Market update
Published
20 Jul 2026 21:41
Source
Stock Titan
Quartr Direct company coverage

Crescent Biopharma (CBIO) Jefferies Global Healthcare Conference 2026 Summary

Crescent Biopharma (CBIO) presented at the Jefferies Global Healthcare Conference 2026, highlighting strong clinical data for HARMONi-6, validating PD-1/VEGF bispecifics, and discussing critical trial design strategies. The company provided updates on its pipeline, focusing on CR

Tone
Positive 73/100
Event
Market update
Published
17 Jul 2026 09:40
Source
Quartr
Moomoo Direct company coverage

Press Release: Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Crescent Biopharma has announced the closing of its public offering, which included 3,000,000 ordinary shares and pre-funded warrants to purchase 3,450,000 ordinary shares, at a price of $4.00 per share or $3.9999 per pre-funded warrant. The offering also saw the full exercise of

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 03:40
Source
Moomoo
Quartr Direct company coverage

Crescent Biopharma (CBIO) Proxy filing Summary

Crescent Biopharma (CBIO) has released a summary of its proxy filing ahead of its Annual General Meeting on June 2, 2026. Key proposals include the election of two Class II directors, ratification of PricewaterhouseCoopers LLP as auditor, and advisory votes on executive compensat

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 20:10
Source
Quartr
Stock Titan Direct company coverage

Crescent Biopharma Offering Closes With 9.4M Shares, Warrants

Crescent Biopharma (CBIO) announced the closing of its underwritten public offering, which included 9,387,896 ordinary shares and pre-funded warrants for up to 525,897 ordinary shares. The offering, priced at $14.50 per ordinary share and $14.499 per pre-funded warrant, generated

Tone
Negative 39/100
Event
Market update
Published
16 Jul 2026 20:10
Source
Stock Titan
GlobeNewswire Direct company coverage

Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Crescent Biopharma, Inc. announced the closing of its public offering, generating approximately $143.7 million in gross proceeds. The offering included 9,387,896 ordinary shares and pre-funded warrants for up to 525,897 ordinary shares, with the underwriters fully exercising thei

Tone
Positive 66/100
Event
Market update
Published
16 Jul 2026 16:01
Source
GlobeNewswire
Quartr Direct company coverage

Crescent Biopharma (CBIO) Bank of America Global Healthcare Conference 2026 Summary

Crescent Biopharma (CBIO) presented at the Bank of America Global Healthcare Conference 2026, outlining its strategic vision in oncology with a focus on a next-gen IO bispecific (CR-001) and an ADC portfolio. The company initiated clinical dosing for CR-001 and CR-003 in early 20

Tone
Positive 75/100
Event
Market update
Published
16 Jul 2026 15:10
Source
Quartr
StreetInsider Direct company coverage

Form 424B5 CRESCENT BIOPHARMA, INC.

Crescent Biopharma, Inc. is offering 8,094,793 ordinary shares and 525,897 pre-funded warrants, with an aim to raise approximately $115.9 million in net proceeds to fund clinical development of its product candidates CR-001, CR-002, and CR-003, as well as for research and develop

Tone
Positive 61/100
Event
Market update
Published
16 Jul 2026 14:42
Source
StreetInsider
Stock Titan Direct company coverage

Crescent Biopharma (Nasdaq: CBIO) prices $125.0 million stock and warrant sale

Crescent Biopharma (Nasdaq: CBIO) has priced a public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $125.0 million in gross proceeds. The offering includes 8,094,793 ordinary shares at $14.50 each and 525,897 pre-funded warrants at $14.499 eac

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:42
Source
Stock Titan
Quiver Quantitative Direct company coverage

Crescent Biopharma Prices $125 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma announced the pricing of a public offering expected to raise approximately $125 million by selling 8,094,793 ordinary shares and 525,897 pre-funded warrants. The ordinary shares are priced at $14.50 each, and the pre-funded warrants at $14.499, with the offerin

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 15:10
Source
Quiver Quantitative
Investing.com Direct company coverage

Crescent Biopharma prices $125M public offering at $14.50/share

Crescent Biopharma Inc. (NASDAQ:CBIO) has priced an underwritten public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $125 million. The shares are priced at $14.50, and the offering is expected to close soon, with major financial institutions

Tone
Negative 40/100
Event
Market update
Published
15 Jul 2026 04:12
Source
Investing.com
Moomoo Direct company coverage

Crescent Biopharma Also Offering Certain Investors Prefunded Warrants to Buy 525,897 Shares >CBIO

Crescent Biopharma has announced an offering to certain investors of prefunded warrants to purchase 525,897 shares. This financial move allows these investors to effectively buy shares at a predetermined price in the future. The offering is likely aimed at raising capital or opti

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 02:39
Source
Moomoo
GlobeNewswire Direct company coverage

Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma has announced the pricing of its underwritten public offering, which includes 8,094,793 ordinary shares at $14.50 per share and pre-funded warrants for up to 525,897 ordinary shares at $14.499 per warrant. The offering is expected to generate approximately $125

Tone
Positive 61/100
Event
Market update
Published
15 Jul 2026 01:47
Source
GlobeNewswire
Stock Titan Direct company coverage

Crescent Biopharma Sets $14.50 Price for 8.1M Shares

Crescent Biopharma (Nasdaq: CBIO) announced the pricing of an underwritten public offering of 8,094,793 ordinary shares at $14.50 per share and 525,897 pre-funded warrants at $14.499 each, expecting to raise approximately $125 million in gross proceeds. The offering is anticipate

Tone
Negative 35/100
Event
Market update
Published
15 Jul 2026 01:47
Source
Stock Titan
marketscreener.com Direct company coverage

Crescent Biopharma Launches Offering of Common Shares, Warrants

Crescent Biopharma Inc. (NasdaqCM:CBIO) has announced an offering of common shares and warrants. This news was published on July 14, 2026, at 4:24 pm EDT. The company specializes in developing therapies for cancer patients, with lead programs including a PD-1 x VEGF bispecific an

Tone
Negative 40/100
Event
Market update
Published
14 Jul 2026 20:24
Source
marketscreener.com
TradingView Direct company coverage

Price to earnings forward of Crescent Biopharma, Inc. – NASDAQ:CBIO

The article focuses on the "Price to earnings forward" metric for Crescent Biopharma, Inc. (NASDAQ: CBIO). It appears to be a truncated financial data page from TradingView, providing basic company and stock market information without detailed financial figures. The content prima

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 19:47
Source
TradingView
GlobeNewswire Direct company coverage

Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma has announced a proposed underwritten public offering of its ordinary shares or pre-funded warrants to purchase ordinary shares. The company also intends to grant underwriters a 30-day option to purchase an additional 15% of ordinary shares. Jefferies, TD Cowen

Tone
Negative 37/100
Event
Market update
Published
14 Jul 2026 19:47
Source
GlobeNewswire
Stock Titan Direct company coverage

Crescent Biopharma Offering Lets Investors Choose Shares or Warrants

Crescent Biopharma (Nasdaq: CBIO) has initiated an underwritten public offering, allowing investors to purchase either ordinary shares or pre-funded warrants. The company reserves a 30-day option for underwriters to acquire an additional 15% of ordinary shares. This offering is p

Tone
Negative 35/100
Event
Market update
Published
14 Jul 2026 19:47
Source
Stock Titan
Stock Titan Direct company coverage

[EFFECT] CRESCENT BIOPHARMA, INC. SEC Filing

This article reports on an SEC filing (Form EFFECT) by CRESCENT BIOPHARMA, INC. (CBIO) which became effective on July 10, 2026. The filing is a Form S-3 (Shelf Registration) and has a neutral impact and sentiment according to StockTitan. The article also provides company overview

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 10:11
Source
Stock Titan